Table 3.

Estimates of treatment differences by visits between OLE and placebo group for different biomarkers in FAS population.

		LS mean (SE)	95% CI	p value
Coll2-1NO2 (pg/mL)	Overall	242 (155)	[–67;550]	0.12
	T1	122 (197)	[–269;512]	0.54
	T3	241 (157)	[–71;554]	0.13
	T6	362 (245)	[–124;848]	0.14
Coll2-1 (nM)	Overall	21.31 (27.06)	[–32.33;74.96]	0.43
	T1	19.95 (29.14)	[–37.8;77.7]	0.5
	T3	8.37 (30.28)	[–51.63;68.37]	0.78
	T6	35.62 (38.87)	[–41.53;112.77]	0.36
PGE2 (pg/mL)	Overall	–22 (64.1)	[–149;105]	0.73
	T1	–48.2 (113.7)	[–274;177]	0.67
	T3	23.5 (79.2)	[–134;181]	0.77
	T6	–41.2 (68.3)	[–177;94.3]	0.55
CTX1 (ng/mL)	Overall	0.03 (0.014)	[0;0.05]	0.09
	T1	0.02 (0.018)	[–0.01;0.06]	0.22
	T3	0.04 (0.02)	[0;0.08]	0.05
	T6	0.02 (0.019)	[–0.02;0.05]	0.45
Osteocalcin (ng/mL)	Overall	0.19 (0.38)	[–0.56;0.94]	0.62
	T1	0.33 (0.39)	[–0.45;1.11]	0.41
	T3	–0.04 (0.45)	[–0.93;0.85]	0.93
	T6	0.28 (0.58)	[–0.87;1.43]	0.63
IL-8 (pg/mL)	Overall	–1.53 (4.26)	[–9.98;6.92]	0.72
	T1	–8.61 (4.85)	[–18.21;1.00]	0.08
	T3	3.26 (10.74)	[–18.04;24.56]	0.76
	T6	0.76 (1.91)	[–3.03;4.56]	0.69
TNF-alpha (pg/mL)	Overall	–0.01 (0.09)	[–0.19;0.17]	0.95
	T1	–0.09 (0.1)	[–0.29;0.11]	0.36
	T3	–0.04 (0.11)	[–0.26;0.18]	0.73
	T6	0.11 (0.13)	[–0.15;0.38]	0.4

CI, confidence interval; LS, least squares; SE, standard error.